Cordant Inc’s Corcept Therapeutics CORT Stock Holding History

Cordant Inc’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-38	Closed	-$1K	–	324
2022 Q1	$1K	Buy	+38	New	+$808	﹤0.01%	904

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cordant Inc's CORT Position: Q2 2022 in Review

Cordant Inc sold out of Corcept Therapeutics (CORT) in Q2 2022, closing a stake of 38 shares — an estimated $1K sold.

Cordant Inc first reported a position in CORT in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2022.

Cordant Inc reported no remaining Corcept Therapeutics position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 38 Corcept Therapeutics shares in Q2 2022, an estimated $1K.
Cordant Inc first reported a position in Corcept Therapeutics in Q1 2022 and held it in 1 quarter.
Cordant Inc's Corcept Therapeutics position peaked at $1K in Q1 2022.
225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.